Delivery Order SPE2DB22D3016-SPE2DB25FBGE0
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM with a ceiling value of $4,383.79 under a firm fixed-price contract structure. This delivery order, issued on August 27, 2025, with an ultimate completion date of August 28, 2025, represents a non-set-aside competitive award supporting federal medical procurement needs. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,347.82 to AmerisourceBergen Drug Corp for the supply of Clindamycin Phosphate 1% Foam in 100GM units. This award, issued on August 21, 2025, represents a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Clindamycin Phosphate 1% Foam in 50-gram units, valued at $1,315.27. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by August 8, 2025. The order will be fulfilled from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its principal...
- The Defense Logistics Agency awarded a delivery order valued at $1,450.14 to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM, a topical antibiotic medication. This non-set-aside, competitively awarded contract reflects a firm fixed price arrangement with an ultimate completion date of August 5, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order valued at $1,072.56 to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM, a topical antibiotic pharmaceutical product. This competitive, non-set-aside contract award was executed on August 7, 2025, with an ultimate completion date of August 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract operates under a firm fixed-price delivery order structure,...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency valued at $2,491.58 for Clindamycin Phosphate 1% Foam 50GM, a topical antibiotic medication. The contract was awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, and represents a firm fixed-price procurement with no set-aside designation. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,538.10 to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM, a topical antibiotic pharmaceutical product. This non-set-aside, competitively awarded delivery order was issued on August 13, 2025, with an ultimate completion date of August 14, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award utilizes firm fixed price pricing and represents a...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of Clindamycin Phosphate 1% Foam, 50 gm. The total ceiling value of the order is $1,077.81. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of medical commodities to support military treatment programs...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of 4565366325 - Clindamycin Phosphate 1% Foam, 50 gm. The order has a firm fixed-price of $2,838.07 and the period of performance runs through August 7, 2024. As a major pharmaceutical distributor, AmerisourceBergen provides a wide range of prescription medications, over-the-counter drugs, and medical supplies to support various government agencies and healthcare programs,...
- This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Clindamycin Phosphate 1% Foam, 100 grams, with a ceiling value of $1,811.64 and a period of performance through June 30, 2025. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBGE0Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 100GM with a ceiling value of $3,700.26 under a firm fixed price contract. This non-set-aside delivery order was executed on August 25, 2025, with an ultimate completion date of August 26, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order represents a single transaction within AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military and veteran healthcare systems. The firm fixed price structure and rapid execution timeline reflect the operational efficiency characteristic of DLA's pharmaceutical supply chain management for Defense Health Agency and other federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 8/25/25 |